| |
LRRK2+/PD-
|
LRRK2+/PD+
|
LRRK2-/PD+
|
LRRK2-/PD-
|
p valuea
|
|---|
|
Gender M(F)
|
11(15)
|
3(12)
|
5(6)
|
0(3)
|
ns
|
|
Age
|
62.5 (56-67.25)
|
58 (53-69)
|
57 (50-64)
|
73 (60-75)
|
ns
|
|
Age at onset
|
NA
|
55 (47-65)
|
57 (50-60)
|
NA
|
ns
|
|
LEDD
|
NA
|
600 (375-662.5)
|
400 (300-600)
|
NA
|
ns
|
|
UPDRS_III
|
4.5 (0-6)
|
18 (15-20)
|
18 (16-22.5)
|
0 (0-0)
|
<0.0001
|
|
MoCA
|
26 (26-28)
|
26 (25-27)
|
27 (26-28)
|
26 (<26-30)
|
0.01
|
|
H&Y
|
0 (0-0)
|
2 (2-2.5)
|
2 (2-2)
|
0 (0-0)
|
<0.0001
|
-
LEDD is L-dopa equivalent daily dosage, UPDRS is Unified Parkinson’s Disease Rating Scale, MoCA is Montreal Cognitive Assessment, H&Y is Hoehn & Yahr scale, NA is not applicable; Values reported are group median (interquartile range). aDetermined by comparing LRRK2+/PD- to LRRK2+/PD+ using the Dunn post hoc test following Kruskal-Wallis test of all groups. ns is not significant as determined by Pearson chi square (gender), ANOVA (age at test), t test (age at onset), Mann-Whitney test (LEDD) and Kruskal-Wallis test (H&Y, UPDRS III)
